Session 9 – Biotech Business Models and Financing Strategy
Date: 23 July (Thursday) 15:40 – 17:10 (GMT+8)
Venue: 701EF, 7F, TaiNEX2 / Online event platform
Board Member and Consultant
Joe McCracken currently advises biopharmaceutical companies on the design and implementation of corporate strategy and business development initiatives; and serves on the Boards of Alkahest, Inc., Kindred Biosciences, Lumos Pharmaceuticals, Modalis Therapeutics, Neuropore Therapies, Regimmune Inc., and Savara Pharmaceuticals. Dr. McCracken was previously Vice President and Global Head of Business Development & Licensing for Roche Pharma, where he was responsible for Roche Pharma’s global in-licensing and out-licensing activities. From October 2009 until July 2011 he was General Manager, Roche Pharma Japan & Asia Regional Head, Roche Partnering. Prior to joining Roche Pharma, Dr. McCracken held the position of Vice President, Business Development at Genentech for more than 9 years, and previously held similar positions at Aventis Pharma and Rhone-Poulenc Rorer. Dr. McCracken holds a Bachelor of Science in Microbiology, a Master of Science in Pharmacology and a Doctorate in Veterinary Medicine from The Ohio State University.
Speech title & Synopsis
Genentech is widely recognized as a leading biotechnology company, with an R&D organization that has changed the practice of medicine. Throughout its history, Genentech has leveraged academic collaborations, in-licensing, out-licensing, and M&A to discover and bring its innovative medicines to patients. Four transactions that transformed Genentech, and lessons learned from these transactions, will be discussed.